DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents.

2.50
Hdl Handle:
http://hdl.handle.net/10541/71933
Title:
DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents.
Authors:
O'Connor, James P B; Jackson, Alan; Parker, Geoff J M; Jayson, Gordon C ( 0000-0002-8515-8944 )
Abstract:
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is now frequently used in early clinical trial assessment of antiangiogenic and vascular disrupting compounds. Evidence of drug efficacy and dose-dependent response has been demonstrated with some angiogenesis inhibitors. This review highlights the critical issues that influence T(1)-weighted DCE-MRI data acquisition and analysis, identifies important areas for future development and reviews the clinical trial findings to date.
Affiliation:
Imaging Science and Biomedical Engineering, University of Manchester, Oxford Road, Manchester M13 9PT, UK.james.o'connor@manchester.ac.uk
Citation:
DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. 2007, 96 (2):189-95 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
29-Jan-2007
URI:
http://hdl.handle.net/10541/71933
DOI:
10.1038/sj.bjc.6603515
PubMed ID:
17211479
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorO'Connor, James P B-
dc.contributor.authorJackson, Alan-
dc.contributor.authorParker, Geoff J M-
dc.contributor.authorJayson, Gordon C-
dc.date.accessioned2009-06-30T11:07:41Z-
dc.date.available2009-06-30T11:07:41Z-
dc.date.issued2007-01-29-
dc.identifier.citationDCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. 2007, 96 (2):189-95 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid17211479-
dc.identifier.doi10.1038/sj.bjc.6603515-
dc.identifier.urihttp://hdl.handle.net/10541/71933-
dc.description.abstractDynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is now frequently used in early clinical trial assessment of antiangiogenic and vascular disrupting compounds. Evidence of drug efficacy and dose-dependent response has been demonstrated with some angiogenesis inhibitors. This review highlights the critical issues that influence T(1)-weighted DCE-MRI data acquisition and analysis, identifies important areas for future development and reviews the clinical trial findings to date.en
dc.language.isoenen
dc.subjectTumour Markersen
dc.subject.meshAngiogenesis Inhibitors-
dc.subject.meshAntineoplastic Agents-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshHumans-
dc.subject.meshMagnetic Resonance Imaging-
dc.subject.meshTumor Markers, Biological-
dc.titleDCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents.en
dc.typeArticleen
dc.contributor.departmentImaging Science and Biomedical Engineering, University of Manchester, Oxford Road, Manchester M13 9PT, UK.james.o'connor@manchester.ac.uken
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.